English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

A ustralia has the highest prevalence of actinic keratoses ( AK ) worldwide. Because of the risk of transformation of  AK  to invasive squamous cell carcinomas, consensus guidelines recommend that  AK  are removed using appropriate therapies to prevent progression to invasive disease. Daylight photodynamic therapy ( PDT ) is emerging as an efficacious treatment for  AK , particularly for patients who require treatment of large areas of chronic actinic damage that can be exposed easily to daylight. Daylight  PDT  with methyl aminolevulinate ( MAL ) cream is a simple treatment for  AK , almost painless, well tolerated and convenient, requiring minimal time in the clinic. Randomised controlled studies from northern  E urope and  A ustralia support the use of daylight  PDT  as an effective therapy for grade  I  and  II AK  on the face and scalp. There is sufficient daylight to conduct daylight  PDT  in  A ustralia at any time of the year and during most weather conditions. Hence, daylight  PDT  with  MAL  can be included as an effective and well‐tolerated new treatment option for the treatment of  AK  in  A ustralia. These consensus recommendations provide guidelines for Australian clinicians on the use of daylight  PDT  in the treatment of diagnosed  AK .

Consensus recommendations on the use of daylight photodynamic therapy with methyl aminolevulinate cream for actinic keratoses in A ustralia